Your request to link to rcsb for Lck

• 1CWD: human p56lck tyrosine kinase complexed with phosphopeptide (10.1006/JMBI.1994.0089 )
• 1CWE: human p56lck tyrosine kinase complexed with phosphopeptide (10.1006/JMBI.1994.0089 )
• 1FBZ: structure-based design of a novel, osteoclast-selective, nonpeptide src sh2 inhibitor with in vivo anti-resorptive activity (10.1073/PNAS.97.17.9373 )
• 1H92: sh3 domain of human lck tyrosine kinase (10.1021/BI015986J )
• 1IJR: crystal structure of lck sh2 complexed with nonpeptide phosphotyrosine mimetic (10.1016/S0960-894X(01)00446-2 )
• 1KIK: sh3 domain of lymphocyte specific kinase (lck) (10.1186/1472-6807-3-3 )
• 1LCJ: sh2 (src homology-2) domain of human p56-lck tyrosine kinase complexed with the 11 residue phosphotyrosyl peptide epqpyeeipiyl (10.1038/362087A0 )
• 1LCK: sh3-sh2 domain fragment of human p56-lck tyrosine kinase complexed with the 10 residue synthetic phosphotyrosyl peptide tegqpyqpqpa (10.1038/368764A0 )
• 1LKK: human p56-lck tyrosine kinase sh2 domain in complex with the phosphotyrosyl peptide ac-ptyr-glu-glu-ile (pyeei peptide) (10.1006/JMBI.1996.0112 )
• 1LKL: human p56-lck tyrosine kinase sh2 domain in complex with the phosphotyrosyl peptide ac-ptyr-glu-glu-gly (pyeeg peptide) (10.1006/JMBI.1996.0112 )
• 1QPC: structural analysis of the lymphocyte-specific kinase lck in complex with non-selective and src family selective kinase inhibitors (10.1016/S0969-2126(99)80086-0 )
• 1QPD: structural analysis of the lymphocyte-specific kinase lck in complex with non-selective and src family selective kinase inhibitors (10.1016/S0969-2126(99)80086-0 )
• 1QPE: structural analysis of the lymphocyte-specific kinase lck in complex with non-selective and src family selective kinase inhibitors (10.1016/S0969-2126(99)80086-0 )
• 1QPJ: crystal structure of the lymphocyte-specific kinase lck in complex with staurosporine. (10.1016/S0969-2126(99)80086-0 )
• 1X27: crystal structure of lck sh2-sh3 with sh2 binding site of p130cas (10.1002/JMR.755 )
• 2IIM: sh3 domain of human lck (10.1016/J.JMB.2006.10.058 )
• 2OF2: crystal structure of furanopyrimidine 8 bound to lck (10.1016/J.BMCL.2007.01.048 )
• 2OF4: crystal structure of furanopyrimidine 1 bound to lck (10.1016/J.BMCL.2007.01.048 )
• 2OFU: x-ray crystal structure of 2-aminopyrimidine carbamate 43 bound to lck (10.1021/JM060435I )
• 2OFV: crystal structure of aminoquinazoline 1 bound to lck (10.1021/JM0605482 )
• 2OG8: crystal structure of aminoquinazoline 36 bound to lck (10.1021/JM0605482 )
• 2PL0: lck bound to imatinib (10.1002/PROT.21633 )
• 2ZM1: crystal structure of imidazo pyrazin 1 bound to the kinase domain of human lck, (auto-phosphorylated on tyr394) (10.1016/J.BMC.2008.10.041 )
• 2ZM4: crystal structure of imidazo quinoxaline 1 bound to the kinase domain of human lck, activated form (auto- phosphorylated on tyr394) (10.1016/J.BMC.2008.10.041 )
• 2ZYB: crystal structure of phenylimidazo pyrazin 2 bound to the kinase domain of human lck, (auto-phosphorylated on tyr394) (10.1016/J.BMC.2008.10.041 )
• 3AC1: crystal structure of pyrazin derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
• 3AC2: crystal structure of pyrazolo pyrimidine derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
• 3AC3: crystal structure of pyrazolo pyrimidine derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
• 3AC4: crystal structure of triazolo pyrimidine derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
• 3AC5: crystal structure of triazolo pyrimidine derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
• 3AC8: crystal structure of pyrazolo pyrimidine derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
• 3ACJ: crystal structure of imidazo pyrimidine derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
• 3ACK: crystal structure of pyrrolo pyrazine derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
• 3AD4: crystal structure of methoxy benzofuran derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
• 3AD5: crystal structure of triazolone derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
• 3AD6: crystal structure of pyrazolo pyrimidine derivative bound to the kinase domain of human lck, (auto-phosphorylated on tyr394)
• 3B2W: crystal structure of pyrimidine amide 11 bound to lck (10.1016/J.BMCL.2007.11.123 )
• 3BYM: x-ray co-crystal structure aminobenzimidazole triazine 1 bound to lck (10.1021/JM701095M )
• 3BYO: x-ray co-crystal structure of 2-amino-6-phenylpyrimido[5', 4':5,6]pyrimido[1,2-a]benzimidazol-5(6h)-one 25 bound to lck (10.1021/JM701095M )
• 3BYS: co-crystal structure of lck and aminopyrimidine amide 10b (10.1021/JM7010996 )
• 3BYU: co-crystal structure of lck and aminopyrimidine reverse amide 23 (10.1021/JM7010996 )
• 3KMM: structure of human lck kinase with a small molecule inhibitor
• 3KXZ: the complex crystal structure of lck with a probe molecule w259 (10.1021/JM901525B )
• 3LCK: the kinase domain of human lymphocyte kinase (lck), activated form (auto-phosphorylated on tyr394) (10.1038/384484A0 )
• 3MPM: lck complexed with a pyrazolopyrimidine (10.1016/J.BMCL.2010.04.112 )
• 4C3F: structure of lck in complex with a compound discovered by virtual fragment linking (10.1021/JM401309Q )
• 4D8K: crystal structure of a sh3-sh2 domains of a lymphocyte-specific protein tyrosine kinase (lck) from homo sapiens at 2.36 a resolution
• 5MTM: monobody mb(lck_3) bound to lck-sh2 domain (10.1016/J.JMB.2017.03.023 )
• 5MTN: monobody mb(lck_1) bound to lck-sh2 (10.1016/J.JMB.2017.03.023 )
• 6PDJ: tyrosine-protein kinase lck bound to compound 11 (10.1021/ACSMEDCHEMLETT.9B00354 )